Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kaufman, Eli ^a   Hall, Sara ^a,b   Surova, Yulia ^a,b   Widner, Håkan ^a,b   Hansson, Oskar ^a,b   Lindqvist, Daniel ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Psychiatry Research Skåne   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DEPRESSION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FATIGUE; FEMALE; HUMAN; INFLAMMATION; MALE; MOTOR DYSFUNCTION; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; SHY DRAGER SYNDROME; SLEEP DISORDER; BLOOD; CASE CONTROL STUDY; MIDDLE AGED;

AGED; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY;

EID: 84876530516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062354     Document Type: Article

References (21)

1. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, et al. (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163: 94-98.
2. Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, et al. (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 38: 4-24.
3. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, et al. (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63: 43-52.
4. Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, et al. (2003) [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 61: 686-689.
5. Schwarz SC, Seufferlein T, Liptay S, Schmid RM, Kasischke K, et al. (1998) Microglial activation in multiple system atrophy: a potential role for NF-kappaB/rel proteins. Neuroreport 9: 3029-3032.
6. Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, et al. (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25: 97-107.
7. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, et al. (2012) Non-motor symptoms in patients with Parkinson's disease- correlations with inflammatory cytokines in serum. PLoS One 7: e47387.
8. Fahn S, Elton RL (1987) UPDRS program members. Unified Parkinsons Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinsons disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information. 153-163.
9. Hoehn MM, Yahr MD, (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
10. Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson's Disease. In: Gillingham FJ, Donaldson IML, editors. Third Symposium of Parkinson's Disease. Edinburgh, Scotland: E&S Livingstone. 152-157.
11. Hagell P, Hoglund A, Reimer J, Eriksson B, Knutsson I, et al. (2006) Measuring fatigue in Parkinson's disease: a psychometric study of two brief generic fatigue questionnaires. J Pain Symptom Manage 32: 420-432.
12. Zigmond AS, Snaith RP, (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361-370.
13. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM, (2003) Assessment of sleep and sleepiness in Parkinson disease. Sleep 26: 1049-1054.
14. Bjelland I, Dahl AA, Haug TT, Neckelmann D, (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52: 69-77.
15. Nishimura M, Kuno S, Kaji R, Kawakami H, (2005) Influence of a tumor necrosis factor gene polymorphism in Japanese patients with multiple system atrophy. Neurosci Lett 374: 218-221.
16. Perry VH, Nicoll JA, Holmes C, (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6: 193-201.
17. Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, et al. (2007) Microglial activation mediates neurodegeneration related to oligodendroglial alphasynucleinopathy:implications for multiple system atrophy. Mov Disord 22: 2196-203.
18. Scalzo P, Kummer A, Cardoso F, Teixeira AL, (2010) Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neuroscience Letters 468: 56-58.
19. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, et al. (2010) The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson's Disease. Psychosomatics 51: 474-479.
20. Muller T, Blum-Degen D, Przuntek H, Kuhn W, (1998) Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 98: 142-144.
21. Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, Sawires M, et al. (2006) Health-related quality of life in multiple system atrophy. Mov Disord 21: 809-815.